Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice
Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of Internal Medicine, University of Heidelberg, Heidel...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-09-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | https://www.dovepress.com/dabigatran-etexilate-retards-the-initiation-and-progression-of-atheros-peer-reviewed-article-DDDT |
| _version_ | 1828232242851217408 |
|---|---|
| author | Preusch MR Ieronimakis N Wijelath ES Cabbage S Ricks J Bea F Reyes M van Ryn J Rosenfeld ME |
| author_facet | Preusch MR Ieronimakis N Wijelath ES Cabbage S Ricks J Bea F Reyes M van Ryn J Rosenfeld ME |
| author_sort | Preusch MR |
| collection | DOAJ |
| description | Michael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany; 3Department of Surgery, University of Washington, Seattle, WA, USA; 4Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; 5Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA Objective: Thrombin has multiple proatherogenic effects including platelet activation and the induction of inflammatory processes. Recently, the cytokine oncostatin M has been shown to have proinflammatory effects. This study was designed to investigate the effects of thrombin inhibition on the initiation and progression of atherosclerosis and on the expression of oncostatin M. Methods: Apolipoprotein E-deficient mice at different ages were fed the thrombin inhibitor dabigatran etexilate. The mean lesion area was measured in the aortic sinus and in the innominate artery. CD45-positive cells within the aortic tissue were measured by flow cytometry. Oncostatin M expression was measured in the tissue sections by immunocytochemistry. Results: Treatment with dabigatran etexilate resulted in a significant reduction of the mean area of atherosclerotic lesions in the aortic sinus in both the young mice (11,176±1,500 µm2 (control) versus 3,822±836 µm2 (dabigatran etexilate), P<0.05) and selectively in the older mice at 28 weeks (234,099±13,500 µm2 (control) versus 175,226±16,132 µm2 (dabigatran etexilate), P<0.05). There were also fewer CD45-positive cells within the aortas of the dabigatran-treated mice and enhanced NO production in endothelial cells pretreated with dabigatran. In addition, the expression of oncostatin M was reduced in the lesions of dabigatran etexilate-treated mice. Conclusion: Inhibition of thrombin by dabigatran retards the development of early lesions and the progression of some established lesions in ApoE-/- mice. It improves endothelial function and retards macrophage accumulation within the vascular wall. Dabigatran also inhibits the expression of oncostatin M, and this suggests that oncostatin M may play a role in the initiation and progression of atherosclerosis. Keywords: macrophages, thrombin, coagulation, inflammation |
| first_indexed | 2024-04-12T19:18:19Z |
| format | Article |
| id | doaj.art-99e1b6d8a9f44cfb9dd1e99c1a5027d3 |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-04-12T19:18:19Z |
| publishDate | 2015-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-99e1b6d8a9f44cfb9dd1e99c1a5027d32022-12-22T03:19:39ZengDove Medical PressDrug Design, Development and Therapy1177-88812015-09-012015default5203521123616Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient micePreusch MRIeronimakis NWijelath ESCabbage SRicks JBea FReyes Mvan Ryn JRosenfeld MEMichael R Preusch,1,2 Nicholas Ieronimakis,1 Errol S Wijelath,3 Sara Cabbage,1 Jerry Ricks,1 Florian Bea,2 Morayma Reyes,1 Joanne van Ryn,4 Michael E Rosenfeld1,5 1Department of Pathology, University of Washington, Seattle, WA, USA; 2Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany; 3Department of Surgery, University of Washington, Seattle, WA, USA; 4Department of CardioMetabolic Disease Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; 5Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA Objective: Thrombin has multiple proatherogenic effects including platelet activation and the induction of inflammatory processes. Recently, the cytokine oncostatin M has been shown to have proinflammatory effects. This study was designed to investigate the effects of thrombin inhibition on the initiation and progression of atherosclerosis and on the expression of oncostatin M. Methods: Apolipoprotein E-deficient mice at different ages were fed the thrombin inhibitor dabigatran etexilate. The mean lesion area was measured in the aortic sinus and in the innominate artery. CD45-positive cells within the aortic tissue were measured by flow cytometry. Oncostatin M expression was measured in the tissue sections by immunocytochemistry. Results: Treatment with dabigatran etexilate resulted in a significant reduction of the mean area of atherosclerotic lesions in the aortic sinus in both the young mice (11,176±1,500 µm2 (control) versus 3,822±836 µm2 (dabigatran etexilate), P<0.05) and selectively in the older mice at 28 weeks (234,099±13,500 µm2 (control) versus 175,226±16,132 µm2 (dabigatran etexilate), P<0.05). There were also fewer CD45-positive cells within the aortas of the dabigatran-treated mice and enhanced NO production in endothelial cells pretreated with dabigatran. In addition, the expression of oncostatin M was reduced in the lesions of dabigatran etexilate-treated mice. Conclusion: Inhibition of thrombin by dabigatran retards the development of early lesions and the progression of some established lesions in ApoE-/- mice. It improves endothelial function and retards macrophage accumulation within the vascular wall. Dabigatran also inhibits the expression of oncostatin M, and this suggests that oncostatin M may play a role in the initiation and progression of atherosclerosis. Keywords: macrophages, thrombin, coagulation, inflammationhttps://www.dovepress.com/dabigatran-etexilate-retards-the-initiation-and-progression-of-atheros-peer-reviewed-article-DDDT |
| spellingShingle | Preusch MR Ieronimakis N Wijelath ES Cabbage S Ricks J Bea F Reyes M van Ryn J Rosenfeld ME Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice Drug Design, Development and Therapy |
| title | Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice |
| title_full | Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice |
| title_fullStr | Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice |
| title_full_unstemmed | Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice |
| title_short | Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice |
| title_sort | dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin m in apolipoprotein e deficient mice |
| url | https://www.dovepress.com/dabigatran-etexilate-retards-the-initiation-and-progression-of-atheros-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT preuschmr dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT ieronimakisn dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT wijelathes dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT cabbages dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT ricksj dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT beaf dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT reyesm dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT vanrynj dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice AT rosenfeldme dabigatranetexilateretardstheinitiationandprogressionofatheroscleroticlesionsandinhibitstheexpressionofoncostatinminapolipoproteinedeficientmice |